Evaluating sacubitril/valsartan as a treatment option for heart failure with reduced ejection fraction and preserved ejection fraction

References

• Murphy SP, Ibrahim NE, Januzzi JL. Heart failure with reduced ejection fraction: a review. JAMA. 2020;324(5):488–504.
   PubMed Web of Science ®Google Scholar
• Rossignol P, Hernandez AF, Solomon SD, et al. Heart failure drug treatment. Lancet Lond Engl. 2019;393(10175):1034–1044.
   PubMed Web of Science ®Google Scholar
• Bozkurt B, Coats AJS, Tsutsui H, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail. 2021;23(3):352–380.
   PubMed Web of Science ®Google Scholar
• Crespo-Leiro MG, Anker SD, Maggioni AP, et al. European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. Eur J Heart Fail. 2016;18(6):613–625.
   PubMed Web of Science ®Google Scholar
• Iacoviello M, Palazzuoli A, Gronda E. Recent advances in pharmacological treatment of heart failure. Eur J Clin Invest. 2021;51(11):e13624.
   PubMed Web of Science ®Google Scholar
• Ponikowski P, Voors AA, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016 [2016];18(8):891–975.
   PubMed Web of Science ®Google Scholar
• Seferovic PM, Ponikowski P, Anker SD, et al. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the heart failure association of the European society of cardiology. Eur J Heart Fail. 2019;21(10):1169–1186.
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Packer M. How should we sequence the treatments for heart failure and a reduced ejection fraction?: a redefinition of evidence-based medicine. Circulation. 2021;143(9):875–877.
   PubMed Web of Science ®Google Scholar
• Bauersachs J. Heart failure drug treatment: the fantastic four. Eur Heart J. 2021;42(6):681–683.
   PubMed Web of Science ®Google Scholar
• Rosano GMC, Moura B, Metra M, et al., Patient profiling in heart failure for tailoring medical therapy. A consensus document of the heart failure association of the European society of cardiology. Eur J Heart Fail. 23(6): 872–881. 2021.
   PubMed Web of Science ®Google Scholar
• McDonagh TA, Metra M, Adamo M, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021:42(36):3599–3726.
   PubMed Web of Science ®Google Scholar
• Wintrich J, Kindermann I, Ukena C, et al. Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future. Clin Res Cardiol. 2020;109(9):1079–1098.
   PubMed Web of Science ®Google Scholar
• Adamczak DM, Oduah M-T, Kiebalo T, et al. Heart failure with preserved ejection fraction-a concise review. Curr Cardiol Rep. 2020;22(9):82.
   PubMed Web of Science ®Google Scholar
• Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383–1392.
   PubMed Web of Science ®Google Scholar
• McMurray JJV, O’Connor C. Lessons from the TOPCAT trial. N Engl J Med. 2014;370(15):1453–1454.
   PubMed Web of Science ®Google Scholar
• Gu J, Noe A, Chandra P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010;50(4):401–414.
   PubMed Web of Science ®Google Scholar
• Ayalasomayajula S, Langenickel TH, Chandra P, et al. Effect of food on the oral bioavailability of the angiotensin receptor - neprilysin inhibitor sacubitril/valsartan (LCZ696) in healthy subjects. Int J Clin Pharmacol Ther. 2016;54:1012–1018.
   PubMed Web of Science ®Google Scholar
• Ayalasomayajula S, Langenickel T, Pal P, et al., Erratum to: clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): a novel angiotensin receptor-neprilysin inhibitor. Clin Pharmacokinet. 57(1): 105–123. 2018.
   PubMed Web of Science ®Google Scholar
• Docherty KF, Vaduganathan M, Solomon SD, et al. Sacubitril/Valsartan: neprilysin inhibition 5 Years after PARADIGM-HF. JACC Heart Fail. 2020;8(10):800–810.
   PubMed Web of Science ®Google Scholar
• McMurray JJV. Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances. Eur J Heart Fail. 2015;17(3):242–247.
   PubMed Web of Science ®Google Scholar
• Nougué H, Pezel T, Picard F, et al. Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study. Eur J Heart Fail. 2019;21(5):598–605.
   PubMed Web of Science ®Google Scholar
• Ibrahim NE, McCarthy CP, Shrestha S, et al. Effect of neprilysin inhibition on various natriuretic peptide assays. J Am Coll Cardiol. 2019;73(11):1273–1284.
   PubMed Web of Science ®Google Scholar
• Vasquez N, Carter S, Grodin JL. Angiotensin receptor-neprilysin inhibitors and the natriuretic peptide axis. Curr Heart Fail Rep. 2020;17(3):67–76.
   PubMedGoogle Scholar
• Packer M, Califf RM, Konstam MA, et al. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Circulation. 2002;106(8):920–926.
   PubMed Web of Science ®Google Scholar
• Langenickel TH, Jordaan P, Petruck J, et al. Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization. Eur J Clin Pharmacol. 2016;72(8):917–924.
   PubMed Web of Science ®Google Scholar
• Okutucu S, Sabanoglu C, Yetis Sayin B, et al. Switching from ramipril to sacubitril/valsartan favorably alters electrocardiographic indices of ventricular repolarization in heart failure with reduced ejection fraction. Acta Cardiol. 2020;75(1):20–25.
   PubMed Web of Science ®Google Scholar
• Yenerçağ M, Arslan U, Dereli S, et al. Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction. Int J Cardiovasc Imaging. 2021;37(1):165–173.
   PubMed Web of Science ®Google Scholar
• Fabris E, Merlo M, Rapezzi C, et al. Sacubitril/Valsartan: updates and clinical evidence for a disease-modifying approach. Drugs. 2019;79(14):1543–1556.
   PubMed Web of Science ®Google Scholar
• Boriani G, De Ponti R, Guerra F, et al. Synergy between drugs and devices in the fight against sudden cardiac death and heart failure. Eur J Prev Cardiol. 2021;28(1):110–123.
   PubMed Web of Science ®Google Scholar
• Zile MR, O’Meara E, Claggett B, et al. Effects of Sacubitril/Valsartan on biomarkers of extracellular matrix regulation in patients with HFrEF. J Am Coll Cardiol. 2019;73(7):795–806.
   PubMed Web of Science ®Google Scholar
• Poglajen G, Anžič-Drofenik A, Zemljič G, et al. Long-Term effects of angiotensin receptor-neprilysin inhibitors on myocardial function in chronic heart failure patients with reduced ejection fraction. Diagn Basel Switz. 2020;10:E522.
   PubMedGoogle Scholar
• Gan L, Langenickel T, Petruck J, et al. Effects of age and sex on the pharmacokinetics of LCZ696, an angiotensin receptor neprilysin inhibitor. J Clin Pharmacol. 2016;56(1):78–86.
   PubMed Web of Science ®Google Scholar
• Ayalasomayajula SP, Langenickel TH, Jordaan P, et al. Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor. Eur J Clin Pharmacol. 2016;72(9):1065–1073.
   PubMed Web of Science ®Google Scholar
• Kulmatycki KM, Langenickel T, Ng WH, et al. Pharmacokinetics and safety of sacubitril/valsartan (LCZ696) in patients with mild and moderate hepatic impairment. Int J Clin Pharmacol Ther. 2017;55(9):728–739.
   PubMed Web of Science ®Google Scholar
• Ruilope LM, Dukat A, Böhm M, et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet Lond Engl. 2010;375(9722):1255–1266.
   PubMed Web of Science ®Google Scholar
• Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet Lond Engl. 2012;380(9851):1387–1395.
   PubMed Web of Science ®Google Scholar
• Senni M, McMurray JJV, Wachter R, et al. Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. Eur J Heart Fail. 2016;18(9):1193–1202.
   PubMed Web of Science ®Google Scholar
• Vardeny O, Claggett B, Kachadourian J, et al. Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial. Eur J Heart Fail. 2019;21(3):337–341.
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Packer M, Desai AS, et al., Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 371(11): 993–1004. 2014.
   PubMed Web of Science ®Google Scholar
• Srivastava PK, Claggett BL, Solomon SD, et al. Estimated 5-Year number needed to treat to prevent cardiovascular death or heart failure hospitalization with angiotensin receptor-neprilysin inhibition vs standard therapy for patients with heart failure with reduced ejection fraction: an analysis of data from the PARADIGM-HF trial. JAMA Cardiol. 2018;3(12):1226–1231.
   PubMed Web of Science ®Google Scholar
• Mogensen UM, Gong J, Jhund PS, et al. Effect of sacubitril/valsartan on recurrent events in the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail. 2018;20(4):760–768.
   PubMed Web of Science ®Google Scholar
• Desai AS, Claggett BL, Packer M, et al. Influence of Sacubitril/Valsartan (LCZ696) on 30-day readmission after heart failure hospitalization. J Am Coll Cardiol. 2016;68(3):241–248.
   PubMed Web of Science ®Google Scholar
• Packer M, McMurray JJV, Desai AS, et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131(1):54–61.
   PubMed Web of Science ®Google Scholar
• Lewis EF, Claggett BL, McMurray JJV, et al. Health-related quality of life outcomes in PARADIGM-HF. Circ Heart Fail. 2017;10(8):e003430.
   PubMed Web of Science ®Google Scholar
• Chandra A, Lewis EF, Claggett BL, et al. Effects of Sacubitril/Valsartan on physical and social activity limitations in patients with heart failure: a secondary analysis of the PARADIGM-HF trial. JAMA Cardiol. 2018;3(6):498–505.
   PubMed Web of Science ®Google Scholar
• Jhund PS, Fu M, Bayram E, et al. Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. Eur Heart J. 2015;36(38):2576–2584.
   PubMed Web of Science ®Google Scholar
• Okumura N, Jhund PS, Gong J, et al. Effects of Sacubitril/Valsartan in the PARADIGM-HF trial (prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure) according to background therapy. Circ Heart Fail. 2016;9(9):e003212.
   PubMed Web of Science ®Google Scholar
• Balmforth C, Simpson J, Shen L, et al. Outcomes and effect of treatment according to etiology in HFrEF: an analysis of PARADIGM-HF. JACC Heart Fail. 2019;7(6):457–465.
   PubMed Web of Science ®Google Scholar
• Solomon SD, Claggett B, Packer M, et al. Efficacy of Sacubitril/Valsartan relative to a prior decompensation: the PARADIGM-HF Trial. JACC Heart Fail. 2016;4(10):816–822.
   PubMed Web of Science ®Google Scholar
• Seferovic JP, Claggett B, Seidelmann SB, et al. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2017;5(5):333–340.
   PubMed Web of Science ®Google Scholar
• Packer M, Claggett B, Lefkowitz MP, et al. Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2018;6(7):547–554.
   PubMed Web of Science ®Google Scholar
• Solomon SD, McMurray JJV, Anand IS, et al., Angiotensin-Neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 381(17): 1609–1620. 2019.
   PubMed Web of Science ®Google Scholar
• Vaduganathan M, McMurray JJV, Solomon SD. Angiotensin receptor–neprilysin inhibition in heart failure with preserved ejection fraction: lessons from PARAGON-HF. Eur J Heart Fail. 2020;22(9):1525–1530.
   PubMed Web of Science ®Google Scholar
• Jackson AM, Jhund PS, Anand IS, et al. Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. Eur Heart J. 2021;42(36):3741–3752.
   PubMed Web of Science ®Google Scholar
• Januzzi JL, Prescott MF, Butler J, et al. Association of change in N-Terminal Pro-B-Type natriuretic peptide following initiation of Sacubitril-Valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA. 2019;322(11):1085–1095.
   PubMed Web of Science ®Google Scholar
• Desai AS, Solomon SD, Shah AM, et al. Effect of Sacubitril-Valsartan vs Enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2019;322(11):1077–1084.
   PubMed Web of Science ®Google Scholar
• Velazquez EJ, Morrow DA, DeVore AD, et al. Angiotensin-Neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019;380(6):539–548.
   PubMed Web of Science ®Google Scholar
• Wachter R, Senni M, Belohlavek J, et al. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. Eur J Heart Fail. 2019;21(8):998–1007.
   PubMed Web of Science ®Google Scholar
• Senni M, Wachter R, Witte KK, et al. Initiation of sacubitril/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: a subgroup analysis of the TRANSITION study. Eur J Heart Fail. 2020;22(2):303–312.
   PubMed Web of Science ®Google Scholar
• Pieske B, Wachter R, Shah SJ, et al. Effect of Sacubitril/Valsartan vs Standard medical therapies on plasma NT-proBNP concentration and submaximal exercise capacity in patients with heart failure and preserved ejection fraction: the PARALLAX randomized clinical trial. JAMA. 2021;326(19):1919–1929.
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Claggett B, Lewis EF, et al. Angiotensin receptor-neprilysin inhibition in acute myocardial infarction. N Engl J Med. 2021;385(20):1845–1855.
   PubMed Web of Science ®Google Scholar
• Proudfoot C, Studer R, Rajput T, et al. Real-world effectiveness and safety of sacubitril/valsartan in heart failure: a systematic review. Int J Cardiol. 2021;331:164–171.
   PubMed Web of Science ®Google Scholar
• Giovinazzo S, Carmisciano L, Toma M, et al. Sacubitril/valsartan in real-life European patients with heart failure and reduced ejection fraction: a systematic review and meta-analysis. ESC Heart Fail. 2021;8(5):3547–3556.
   PubMed Web of Science ®Google Scholar
• McCormack PL. Sacubitril/Valsartan: a review in chronic heart failure with reduced ejection fraction. Drugs. 2016;76(3):387–396.
   PubMed Web of Science ®Google Scholar
• Pereira G ME, Duarte G S, Katerenchuk V, et al. Safety and tolerability of sacubitril-valsartan: a systematic review and meta-analysis. Expert Opin Drug Saf. 2021;20(5):577–588.
   PubMed Web of Science ®Google Scholar
• Poorgolizadeh E, Homayouni Moghadam F, Dormiani K, et al. Do neprilysin inhibitors walk the line? Heart ameliorative but brain threatening! Eur J Pharmacol. 2021;894:173851.
   PubMed Web of Science ®Google Scholar
• Cannon JA, Shen L, Jhund PS, et al. Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. Eur J Heart Fail. 2017;19(1):129–137.
   PubMed Web of Science ®Google Scholar
• Langenickel TH, Tsubouchi C, Ayalasomayajula S, et al. The effect of LCZ696 (sacubitril/valsartan) on amyloid-β concentrations in cerebrospinal fluid in healthy subjects. Br J Clin Pharmacol. 2016;81(5):878–890.
   PubMed Web of Science ®Google Scholar
• Pérez-Roselló V, Batalla-Monedero M, Sánchez-Lázaro I, et al. Three cases of psychosis after use of sacubitril/valsartan. Rev Espanola Cardiol Engl Ed. 2021;74(1):103–105.
   PubMed Web of Science ®Google Scholar
• Wooster J, Cook EA, Shipman D. Psychiatric manifestations with Sacubitril/Valsartan: a case report. J Pharm Pract. 2020;33(4):553–557.
   PubMed Web of Science ®Google Scholar
• Moulis F, Rousseau V, Chebane L, et al. Serious adverse drug reactions with sacubitril/valsartan Entresto®: a French pharmacovigilance survey. Eur J Clin Pharmacol. 2018;74(7):983–984.
   PubMed Web of Science ®Google Scholar
• Patel NM, Stottlemyer BA, Gray MP, et al. A Pharmacovigilance study of adverse drug reactions reported for cardiovascular disease medications approved between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database. Cardiovasc Drugs Ther. 2021. DOI:https://doi.org/10.1007/s10557-021-07157-3.
   Google Scholar
• Bejan-Angoulvant T, Genet T, Vrignaud L, et al. Three case reports of involuntary muscular movements as adverse reactions to sacubitril/valsartan. Br J Clin Pharmacol. 2018;84(5):1072–1074.
   PubMed Web of Science ®Google Scholar
• Guion-Firmin J, Tessier S, Lepelley M, et al. Diarrhoea with the angiotensin receptor neprilysin inhibitor sacubitril + valsartan: a pharmacovigilance study. Fundam Clin Pharmacol. 2021. https://doi.org/10.1111/fcp.12717.
   Google Scholar
• Gatti M, Antonazzo IC, Diemberger I, et al. Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system. Eur J Prev Cardiol. 2021;28(9):983–989.
   PubMed Web of Science ®Google Scholar
• Eadie AL, Brunt KR, Herder M. Exploring the food and drug administration’s review and approval of Entresto (sacubitril/valsartan). Pharmacol Res Perspect. 2021;9(3):e00794.
   PubMed Web of Science ®Google Scholar
• Fiuzat M, Lowy N, Stockbridge N, et al. Endpoints in heart failure drug development: history and future. JACC Heart Fail. 2020;8(6):429–440.
   PubMed Web of Science ®Google Scholar
• Vaduganathan M, Claggett BL, Jhund PS, et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet Lond Engl. 2020;396(10244):121–128.
   PubMed Web of Science ®Google Scholar
• Committee W, Maddox TM, Januzzi JL, et al. Update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American college of cardiology solution set oversight committee. J Am Coll Cardiol. 2021;77(6):772–810. 2021.
   PubMed Web of Science ®Google Scholar
• Liu X-Q, He L-S, Huang J-Q, et al. Cost-effectiveness analyses of sacubitril-valsartan for heart failure. Heart Fail Rev. 2021;26:1119–1130.
   PubMed Web of Science ®Google Scholar
• Hollenberg SM, Warner Stevenson L, Ahmad T, et al. ACC expert consensus decision pathway on risk assessment, management, and clinical trajectory of patients hospitalized with heart failure a report of the American college of cardiology solution set oversight committee. J Am Coll Cardiol. 2019 [2019];74(15):1966–2011.
   PubMed Web of Science ®Google Scholar
• Ntalianis A, Chrysohoou C, Giannakoulas G, et al. Angiotensin receptor-neprilysin inhibition in patients with acute decompensated heart failure: an expert consensus position paper. Heart Fail Rev. 2021; https://doi.org/10.1007/s10741-021-10115-8
   Google Scholar
• Di Tano G, Di Lenarda A, Iacoviello M, et al. ANMCO POSITION PAPER: use of sacubitril/valsartan in hospitalized patients with acute heart failure. Eur Heart J Suppl J Eur Soc Cardiol. 2021;23(Supplement_C):C176–C183.
   PubMed Web of Science ®Google Scholar
• Sabouret P, Attias D, Beauvais C, et al. Diagnosis and management of heart failure from hospital admission to discharge: a practical expert guidance. Ann Cardiol Angeiol (Paris). 2021;S0003-3928(21):68–78.
   Google Scholar
• Entresto: EPAR product information - Summary of product characteristics. Last update13/July/2021. Accessed 04 January 2022. Available from: https://www.ema.europa.eu/en/documents/product-information/entresto-epar-product-information_en.pdf
   Google Scholar
• Entresto: prescribing Information. Last update 16/February/2021. Accessed 04 January 2022. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/207620s018lbl.pdf
   Google Scholar
• Solomon SD, Vaduganathan M, Claggett B, et al. Sacubitril/Valsartan across the spectrum of ejection fraction in heart failure. Circulation. 2020;141(5):352–361.
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Jackson AM, Lam CSP, et al. Effects of Sacubitril-Valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction: insights from PARAGON-HF. Circulation. 2020;141(5):338–351.
   PubMed Web of Science ®Google Scholar
• Vaduganathan M, Claggett BL, Desai AS, et al. Prior heart failure hospitalization, clinical outcomes, and response to Sacubitril/Valsartan compared with valsartan in HFpEF. J Am Coll Cardiol. 2020;75(3):245–254.
   PubMed Web of Science ®Google Scholar
• Volpe M, Bauersachs J, Bayés-Genís A, et al. Sacubitril/valsartan for the management of heart failure: a perspective viewpoint on current evidence. Int J Cardiol. 2021;327:138–145.
   PubMed Web of Science ®Google Scholar
• Butler J, Anstrom K J, Armstrong P W. Comparing the Benefit of Novel Therapies Across Clinical Trials. Circulation. 2020;142(8):717–719. https://doi.org/10.1161/CIRCULATIONAHA.120.047086.
   PubMed Web of Science ®Google Scholar
• Yan Y, Liu B, Du J, et al. SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and meta-analysis. ESC Heart Fail. 2021;8(3):2210–2219.
   PubMed Web of Science ®Google Scholar
• Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–1424.
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.
   PubMed Web of Science ®Google Scholar
• Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020 May 14;382(20):1883–1893.
   PubMed Web of Science ®Google Scholar
• Dębska-Kozłowska A, Książczyk M, Lelonek M. Where are we in 2021 with heart failure with reduced ejection fraction?-current outlook and expectations from new promising clinical trials. Heart Fail Rev. 2021. https://doi.org/10.1007/s10741-021-10120-x
   Google Scholar
• Silva-Cardoso J, Fonseca C, Franco F, et al. Optimization of heart failure with reduced ejection fraction prognosis-modifying drugs: a 2021 heart failure expert consensus paper. Rev Port Cardiol (Engl Ed). 2021;40(12):975–983.
   PubMedGoogle Scholar
• Carnicelli AP, Li Z, Greiner MA, et al. Sacubitril/Valsartan adherence and postdischarge outcomes among patients hospitalized for heart failure with reduced ejection fraction. JACC Heart Fail. 2021;S2213-1779(21):335–338.
   Google Scholar
• Zannad F, Ferreira JP, Pocock SJ, et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet. 2020;396(10254):819–829.
   PubMed Web of Science ®Google Scholar
• Packer M, Anker SD, Butler J, et al. Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. Eur Heart J. 2021;42(6):671–680.
   PubMed Web of Science ®Google Scholar
• Hsiao F-C, Lin C-P, Tung Y-C, et al. Combining sodium-glucose cotransporter 2 inhibitors and angiotensin receptor-neprilysin inhibitors in heart failure patients with reduced ejection fraction and diabetes mellitus: a multi-institutional study. Int J Cardiol. 2021;330:91–97.
   PubMed Web of Science ®Google Scholar
• Nagamine T. BRASH syndrome associated with angiotensin receptor blocker and SGLT2 inhibitor. Cjem. 2021. https://doi.org/10.1007/s43678-021-00213-9
   Google Scholar
• Mewton N, Girerd N, Boffa -J-J, et al. Practical management of worsening renal function in outpatients with heart failure and reduced ejection fraction: statement from a panel of multidisciplinary experts and the heart failure working group of the French society of cardiology. Arch Cardiovasc Dis. 2020;113(10):660–670.
   PubMed Web of Science ®Google Scholar
• Cautela J, Tartiere J-M, Cohen-Solal A, et al. Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients. Eur J Heart Fail. 2020;22(8):1357–1365.
   PubMed Web of Science ®Google Scholar
• Pontremoli R, Borghi C, Filardi PP. Renal protection in chronic heart failure: focus on sacubitril/valsartan. Eur Heart J Cardiovasc Pharmacother. 2021;7(5):445–452.
   PubMed Web of Science ®Google Scholar
• Ferrari R, Fucili A, Rapezzi C. Understanding the results of the PARAGON-HF trial. Eur J Heart Fail. 2020;22(9):1531–1535.
   PubMed Web of Science ®Google Scholar
• Pocock SJ, Rossello X, Owen R, et al. Primary and secondary outcome reporting in randomized trials: JACC state-of-the-art review. J Am Coll Cardiol. 2021;78(8):827–839.
   PubMed Web of Science ®Google Scholar
• Packer M, Zannad F, Anker SD. Heart failure and a preserved ejection fraction: a side-by-side examination of the PARAGON-HF and EMPEROR-preserved trials. Circulation. 2021;144(15):1193–1195.
   PubMed Web of Science ®Google Scholar
• Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451–1461.
   PubMed Web of Science ®Google Scholar
• Mann DL, Givertz MM, Vader JM, et al. Effect of treatment with Sacubitril/Valsartan in patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA Cardiol. 2021. https://doi.org/10.1001/jamacardio.2021.4567.
   Google Scholar
• Martín‐Garcia A, López‐Fernández T, Mitroi C, et al. Effectiveness of sacubitril–valsartan in cancer patients with heart failure. ESC Heart Fail. 2020;7(2):763–767.
   PubMed Web of Science ®Google Scholar
• Gregorietti V, Fernandez TL, Costa D, et al. Use of Sacubitril/valsartan in patients with cardio toxicity and heart failure due to chemotherapy. Cardio-Oncol. 2020;6(1):24.
   PubMedGoogle Scholar